Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Incidence and Associated Risk Factors in the Development of Carfilzomib-Induced Cardiovascular Toxicity.
Journal: Current oncology (Toronto, Ont.)
Published: June 22, 2026
From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma.
Journal: Expert review of hematology
Published: May 27, 2026
The ClinicalTrials.gov Landscape of Multiple Myeloma Clinical Trials: A 20-Year Analysis of Geographic Distribution and Growth Patterns: USMIRC Analysis.
Journal: Current oncology (Toronto, Ont.)
Published: May 05, 2026
Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC.
Journal: Current oncology (Toronto, Ont.)
Published: March 17, 2026
High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis.
Journal: Current oncology (Toronto, Ont.)
Published: March 11, 2026
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma.
Journal: American journal of hematology
Published: February 20, 2026
Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment Failure.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 05, 2026
Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib-Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis.
Journal: Current oncology (Toronto, Ont.)
Published: January 30, 2026
Aggressive Plasmablastic Myeloma with Retroperitoneal Extramedullary Plasmacytoma.
Journal: Kansas journal of medicine
Published: January 29, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.
Journal: Blood cancer journal
Published: November 04, 2025
Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience.
Journal: Clinical lymphoma, myeloma & leukemia
Published: June 25, 2025
Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure.
Journal: Frontiers in oncology
Published: February 17, 2025
Last Updated: 09/26/2026